These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 7594334

  • 1. Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine.
    Sakaguchi M, Ashida K, Umegaki E, Miyoshi H, Katsu K.
    J Clin Gastroenterol; 1995; 20 Suppl 2():S27-31. PubMed ID: 7594334
    [Abstract] [Full Text] [Related]

  • 2. Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine.
    Tsuji S, Kawano S, Higashi T, Mukuda T, Imaizumi T, Tatsumi T, Miura N, Miyajima K, Fukuda M, Noguchi M.
    J Clin Gastroenterol; 1995; 20 Suppl 2():S1-4. PubMed ID: 7594320
    [Abstract] [Full Text] [Related]

  • 3. Comparison of lansoprazole and famotidine for gastric ulcer by endoscopic ultrasonography: a preliminary trial.
    Okai T, Sawabu N, Songür Y, Motoo Y, Watanabe H.
    J Clin Gastroenterol; 1995; 20 Suppl 2():S32-5. PubMed ID: 7594335
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring.
    Takeda H, Hokari K, Asaka M.
    J Clin Gastroenterol; 1995; 20 Suppl 1():S7-9. PubMed ID: 7673616
    [Abstract] [Full Text] [Related]

  • 5. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.
    Shirai N, Furuta T, Xiao F, Kajimura M, Hanai H, Ohashi K, Ishizaki T.
    Aliment Pharmacol Ther; 2002 Apr; 16(4):837-46. PubMed ID: 11929404
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
    Ogawa N.
    Nihon Rinsho; 1992 Jan; 50(1):68-73. PubMed ID: 1347332
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The therapeutic effect of proton pump inhibitors on Helicobacter pylori-positive gastric ulcers.
    Sasakii M, Joh T, Yokoyama Y, Seno K, Tsuchida K, Kurokawa T, Itoh M.
    J Pharm Pharmacol; 1999 Jul; 51(7):825-30. PubMed ID: 10467958
    [Abstract] [Full Text] [Related]

  • 12. Four-day continuous gastric pH monitoring following anti-acid secretory drug administration: cross-over test to assess the early effects.
    Suzuki T, Yamaguchi T, Odaka T, Kobayashi M, Seza A, Kouzu T, Yokosuka O.
    Aliment Pharmacol Ther; 2008 Jan 01; 27(1):66-71. PubMed ID: 17922801
    [Abstract] [Full Text] [Related]

  • 13. Effects of rabeprazole or famotidine during cardiac surgery on perioperative gastric and esophageal pH readings.
    Gon S, Irie Y, Takahashi M.
    Jpn J Thorac Cardiovasc Surg; 2006 Jul 01; 54(7):278-84. PubMed ID: 16898640
    [Abstract] [Full Text] [Related]

  • 14. In single doses ranitidine effervescent is more effective than lansoprazole in decreasing gastric acidity.
    Arnestad JS, Kleveland PM, Waldum HL.
    Aliment Pharmacol Ther; 1997 Apr 01; 11(2):355-8. PubMed ID: 9146775
    [Abstract] [Full Text] [Related]

  • 15. Endoscopic ultrasonographic evaluation of gastric ulcer healing on treatment with proton pump inhibitors versus H2-receptor antagonists.
    Tanaka M, Maruoka A, Chijiiwa Y, Tanaka M, Nawata H.
    Scand J Gastroenterol; 1994 Dec 01; 29(12):1140-4. PubMed ID: 7886404
    [Abstract] [Full Text] [Related]

  • 16. Effects of lansoprazole on gastric ulcer healing and mucin content.
    Komuro Y, Ishii K, Miyake Y, Tanabe S, Oida M, Saigenji K.
    J Clin Gastroenterol; 1995 Dec 01; 20 Suppl 2():S47-51. PubMed ID: 7594339
    [Abstract] [Full Text] [Related]

  • 17. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S.
    Aliment Pharmacol Ther; 2002 Oct 01; 16(10):1811-7. PubMed ID: 12269976
    [Abstract] [Full Text] [Related]

  • 18. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
    Katz PO, Hatlebakk JG, Castell DO.
    Aliment Pharmacol Ther; 2000 Jun 01; 14(6):709-14. PubMed ID: 10848653
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects.
    Geus WP, Mulder PG, Nicolai JJ, Van den Boomgaard DM, Lamers CB.
    Aliment Pharmacol Ther; 1998 Apr 01; 12(4):329-35. PubMed ID: 9690721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.